Peptide Profile
CJC / IPA Blend
GHRH analog + growth hormone secretagogue
CLINICAL DEVELOPMENT STAGE:
Not Established
CJC-1295 (No DAC) + Ipamorelin is an investigational peptide combination designed to influence growth hormone signaling through two complementary pathways. CJC-1295 No DAC is a growth hormone-releasing hormone analog, while ipamorelin is a growth hormone secretagogue that acts through the ghrelin receptor pathway. The combination itself has not been established as an FDA-approved therapy.
Compound Overview
Classification
GHRH analog + growth hormone secretagogue
Regulatory Status
Investigational · Combination not FDA approved
Targets / Receptors
GHRH receptor pathway; ghrelin/growth hormone secretagogue receptor (GHSR) pathway
Research Focus
Growth hormone secretion; growth hormone-releasing hormone signaling; ghrelin receptor signaling; IGF-1 regulation; endocrine physiology; and the interaction between GHRH analogs and growth hormone secretagogues.
Mechanism of Action
CJC-1295 No DAC and ipamorelin influence growth hormone secretion through different signaling pathways.
CJC-1295 No DAC is a modified growth hormone-releasing hormone analog intended to stimulate the GHRH receptor pathway in the pituitary. Ipamorelin is a pentapeptide growth hormone secretagogue that acts through the ghrelin, or growth hormone secretagogue, receptor and has been shown in human volunteers to produce a discrete episode of growth hormone release.
Because the compounds act through complementary receptor systems, the combination is commonly studied in the context of coordinated growth hormone signaling. However, clinical evidence for the specific CJC-1295 No DAC plus ipamorelin combination is limited, and findings from studies of either compound individually should not be assumed to establish the safety or efficacy of the combination.
Research Evidence
Human evidence for the two components differs substantially, and published clinical evidence specifically evaluating the CJC-1295 No DAC + Ipamorelin combination is limited.
Ipamorelin has been studied in healthy volunteers, where it demonstrated dose-proportional pharmacokinetics and stimulated growth hormone release across tested dose levels. In a later Phase 2 study involving 117 patients undergoing bowel resection, ipamorelin was evaluated for postoperative ileus. The treatment was generally well tolerated, but did not demonstrate a statistically significant improvement in the primary efficacy endpoint compared with placebo.
Published human studies of CJC-1295 have primarily evaluated the long-acting DAC-modified form rather than CJC-1295 No DAC. Those studies demonstrated sustained increases in growth hormone and IGF-1; however, those findings should not be directly attributed to CJC-1295 No DAC, because removal of the DAC modification materially changes the compound’s pharmacokinetic properties.
The CJC-1295 No DAC + Ipamorelin combination remains investigational and is not FDA approved. Evidence from studies of the individual compounds or different CJC-1295 formulations should not be interpreted as establishing the safety or efficacy of the combination.
Safety & Limitations
The safety profile of the CJC-1295 No DAC plus ipamorelin combination has not been established in large, controlled clinical trials.
FDA has identified potential safety concerns associated with compounded products containing CJC-1295 and ipamorelin, including immunogenicity, peptide-related impurities, and limitations in available clinical safety data. FDA also notes serious adverse events reported in association with CJC-1295 and with intravenous ipamorelin in clinical research.
Evidence from studies of one component, one formulation, or one route of administration should not be assumed to establish the safety of another formulation or of the combination. The product remains investigational and is not FDA approved.
Key References
Ipamorelin has reached human clinical investigation. In a randomized Phase 2 trial involving 117 patients undergoing bowel resection, ipamorelin was evaluated for postoperative ileus. The study found no statistically significant improvement in the primary efficacy endpoint compared with placebo. View study on PubMed.
Human CJC-1295 research has demonstrated effects on the GH/IGF-1 axis, but the principal published clinical studies evaluated the long-acting DAC form. In healthy adults, CJC-1295 with DAC produced dose-dependent increases in growth hormone and IGF-1, with an estimated half-life of 5.8–8.1 days. These results should not be directly extrapolated to CJC-1295 No DAC. View study on PubMed.
CJC-1295 with DAC was also shown to preserve pulsatile growth hormone secretion. A separate human study found increased mean GH and IGF-1 levels while GH pulsatility was maintained. Again, this research involved the long-acting DAC-modified compound rather than CJC-1295 No DAC. View study on PubMed.
Published controlled human evidence for the specific CJC-1295 No DAC + Ipamorelin combination remains limited. Evidence involving either component individually—or CJC-1295 with DAC—should not be interpreted as demonstrating the safety or efficacy of the No DAC + Ipamorelin combination.
FDA has identified safety concerns and significant gaps in the available clinical data for both CJC-1295 and ipamorelin. The agency cites concerns including immunogenicity, peptide-related impurities and limited safety information; it has also identified serious adverse events associated with CJC-1295 and intravenous ipamorelin in clinical research. Review the FDA safety information.
Last scientifically reviewed: 09/08/2026